

Michael Loschi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4531090/publications.pdf>

Version: 2024-02-01

39
papers

1,218
citations

567281

15
h-index

395702

33
g-index

40
all docs

40
docs citations

40
times ranked

2086
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e199-e205.	0.4	2
2	Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients. <i>Blood</i> , 2022, 139, 134-137.	1.4	59
3	Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report. <i>Bone Marrow Transplantation</i> , 2022, 57, 315-318.	2.4	36
4	Retinoic acid signaling acts as a rheostat to balance Treg function. , 2022, 19, 820-833.		8
5	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , 2021, 56, 917-927.	2.4	8
6	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. <i>Blood</i> , 2021, 137, 1090-1103.	1.4	8
7	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. <i>Blood Advances</i> , 2021, 5, 176-184.	5.2	56
8	Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: a Soci�t� Francophone de Greffe de Moelle et de Th�rapie cellulaire (SFGM-TC) multicentre cohort study. <i>British Journal of Haematology</i> , 2021, 192, e121-e124.	2.5	36
9	FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5873.	4.1	9
10	Eye amputation following lifitegrast treatment for ocular graft-versus-host disease: First case report. <i>Journal Francais D'Ophtalmologie</i> , 2021, 44, 652-657.	0.4	6
11	Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des My�lodysplasies (GFM). <i>Journal of Clinical Oncology</i> , 2021, 39, 1575-1583.	1.6	169
12	Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10105.	4.1	15
13	A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2). <i>Blood</i> , 2021, 138, 3643-3643.	1.4	7
14	Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk". <i>Blood</i> , 2021, 138, 1842-1842.	1.4	2
15	Impact of Pre-Graft Ruxolitinib on Post-Transplantation Outcome in Myelofibrosis Patients. <i>Blood</i> , 2021, 138, 1844-1844.	1.4	0
16	Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program. <i>Blood</i> , 2021, 138, 262-262.	1.4	7
17	Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Blood</i> , 2021, 138, 336-336.	1.4	2
18	Mitochondrial Integrity Regulated by Lipid Metabolism Is a Cell-Intrinsic Checkpoint for Treg Suppressive Function. <i>Cell Metabolism</i> , 2020, 31, 422-437.e5.	16.2	215

#	ARTICLE	IF	CITATIONS
19	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. <i>Blood</i> , 2020, 135, 28-40.	1.4	14
20	Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program. <i>Blood</i> , 2020, 136, 15-15.	1.4	5
21	Risk Factors for Severe Form of COVID-19 after Allogeneic Hematopoietic Stem Cell Transplantation: A SFGM-TC Multicentre Cohort Study. <i>Blood</i> , 2020, 136, 34-34.	1.4	0
22	Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. <i>Blood</i> , 2019, 134, 1670-1682.	1.4	49
23	Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality. <i>Journal of Immunology</i> , 2019, 202, 2795-2805.	0.8	10
24	Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease. <i>JCI Insight</i> , 2019, 4, .	5.0	18
25	CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations (TP53, ASXL1.) Tj ETQq1 1 0.784314 rgBT /Omer Cohort. <i>Blood</i> , 2019, 134, 1355-1355.	1.4	5
26	Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers. <i>Haematologica</i> , 2018, 103, e103-e105.	3.5	16
27	Cutting Edge: TGF- β ² and Phosphatidylinositol 3-Kinase Signals Modulate Distinct Metabolism of Regulatory T Cell Subsets. <i>Journal of Immunology</i> , 2018, 201, 2215-2219.	0.8	58
28	Effects of MicroRNA on Regulatory T Cells and Implications for Adoptive Cellular Therapy to Ameliorate Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 57.	4.8	46
29	Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice. <i>Molecular Therapy</i> , 2018, 26, 1423-1434.	8.2	37
30	The vimentin intermediate filament network restrains regulatory T cell suppression of graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2018, 128, 4604-4621.	8.2	32
31	ST2 and ROR- β Roles in Intestinal Regulatory T Cells. <i>Blood</i> , 2018, 132, 66-66.	1.4	0
32	Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA. <i>Leukemia Research</i> , 2017, 54, 12-16.	0.8	2
33	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF- β ² production. <i>Blood</i> , 2017, 129, 2570-2580.	1.4	122
34	Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the Apre-breventuximab vedotin era: A LYSA/SFGM-TC study. <i>European Journal of Cancer</i> , 2017, 83, 146-153.	2.8	18
35	Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. <i>American Journal of Hematology</i> , 2016, 91, 366-370.	4.1	110
36	High Number of Memory T Cells Is Associated with Higher Risk of Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 569-574.	2.0	18

#	ARTICLE	IF	CITATIONS
37	Invasive Aspergillosis in Neutropenic Patients During Hospital Renovation: Effectiveness of Mechanical Preventive Measures in a Prospective Cohort of 438 Patients. <i>Mycopathologia</i> , 2015, 179, 337-345.	3.1	10
38	Severe Acquired Neutropenia Associated with Anti-Proteinase 3 Antibodies. <i>Acta Haematologica</i> , 2011, 126, 211-213.	1.4	2
39	Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 0, ...	2.4	1